Our previous study found that miR-342-5p could target CCND1 to affect imatinib resistance by assessing the differential expression of miRNAs in peripheral blood mononuclear cell (PBMC) from CML patients compared to healthy donors (16). Here, CCND1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.